glp-1 news today september 29 2025 Nutritional priorities to support therapy for obesity: A joint advisory from the American College of Lifestyle Medicine, the American Society for Nutrition, the Obesity Medicine Association, and the Obesity Society New oral GLP-1 drugs could

The critical context: Lean mass loss on a GLP-1 lands in roughly the same range as lifestyle-based weight loss about 2030% of total weight lost

In some contexts, such cross-linking provided potent agonists, but other cross-linking efforts caused sharp declines in potency

Cessation and reduction in alcohol consumption and misuse after psychedelic use

Fogyaszts eltt felrzand

Tirzepatide, a dual GLP-1 and GIP receptor agonist, has a half-life closer to 5 days, placing it between weekly injectables and daily oral formulations in terms of duration

Trichoderma harzianum ETS 323-mediated resistance in Brassica oleracea var